Who is sponsoring NCT04253730?

NCT04253730 is sponsored by University of Manitoba.

What drugs are being tested in NCT04253730?

Interventions in NCT04253730: Cold Stress.

What condition does NCT04253730 study?

NCT04253730 studies Hypothermia Due to Cold Environment.

Is NCT04253730 still recruiting?

NCT04253730 is currently completed. Last updated 6 December 2022.

Last reviewed 2022-12-06 · How we verify

NCT04253730

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Characterization of Corticospinal Excitability During Progressive Skin Cooling

Completed NA Last updated 6 December 2022

What this trial tests

NA trial testing Cold Stress in Hypothermia Due to Cold Environment in 10 participants. Completed in 1 June 2022.

Timeline

22 August 2019

Primary endpoint
1 March 2022

1 June 2022

Quick facts

Lead sponsor	University of Manitoba
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	10
Start date	22 August 2019
Primary completion	1 March 2022
Estimated completion	1 June 2022
Sites	1 location across Canada

Drugs / interventions tested

Cold Stress

Conditions studied

Hypothermia Due to Cold Environment — all drugs for Hypothermia Due to Cold Environment →

Sponsor

University of Manitoba

Who can join

Adults 18 to 45, any sex, with Hypothermia Due to Cold Environment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study characterizes the changes in corticospinal excitability that accompany basic cold stress via skin cooling that result in reduced skin or core temperature and shivering.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Spinal and corticospinal excitability in response to reductions in skin and core temperatures via whole-body cooling.
Hurrie DMG, Talebian Nia M, Power K, Stecina K, et al · · 2022 · cited 5× · PMID 34582724 · DOI 10.1139/apnm-2021-0370

Verify or expand the search:

Other University of Manitoba trials

Trials by the same sponsor.

NCT07528417 — Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX) · Phase 2 · not yet recruiting
NCT07366515 — Feasibility of a Multimodal Virtual Reality Intervention to Reduce Preoperative Anxiety in Cancer Surgery Patients · NA · not yet recruiting
NCT07354386 — Effects of Dried Whole Fruits on Metabolism in Diabetes · NA · enrolling by invitation
NCT07361315 — Development and Online Evaluation of an Online Course for Parasomnias · NA · recruiting
NCT07023744 — CANnabinoids for Drug Resistant Epilepsy (DRE) in Adults and Children · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04253730 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Manitoba
Last refreshed: 6 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04253730.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing